Allscripts Healthcare Solutions (NASDAQ: MDRX) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Insider and Institutional Ownership

96.4% of Omnicell shares are held by institutional investors. 0.8% of Allscripts Healthcare Solutions shares are held by insiders. Comparatively, 3.8% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for Allscripts Healthcare Solutions and Omnicell, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allscripts Healthcare Solutions 1 7 9 0 2.47
Omnicell 0 2 6 0 2.75

Allscripts Healthcare Solutions presently has a consensus target price of $14.47, suggesting a potential upside of 11.80%. Omnicell has a consensus target price of $49.00, suggesting a potential upside of 1.34%. Given Allscripts Healthcare Solutions’ higher probable upside, equities analysts clearly believe Allscripts Healthcare Solutions is more favorable than Omnicell.

Valuation and Earnings

This table compares Allscripts Healthcare Solutions and Omnicell’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Allscripts Healthcare Solutions $1.66 billion 1.41 $160.09 million ($1.06) -12.21
Omnicell $680.15 million 2.66 $42.68 million ($0.22) -219.77

Allscripts Healthcare Solutions has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than Allscripts Healthcare Solutions, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Allscripts Healthcare Solutions has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.

Profitability

This table compares Allscripts Healthcare Solutions and Omnicell’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Allscripts Healthcare Solutions -11.54% 5.97% 1.96%
Omnicell -1.14% 0.41% 0.19%

Allscripts Healthcare Solutions Company Profile

Allscripts Healthcare Solutions, Inc. (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions. The Population Health segment includes the sale of health management and coordinated care solutions, which focus on hospitals, health systems, other care facilities and accountable care organizations (ACOs). The Netsmart segment provides software and technology solutions to the health and human services industry, which includes behavioral health, addiction treatment, intellectual and developmental disability services, child and family services and public health segments, as well as to post-acute home care organizations.

Omnicell Company Profile

Omnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment is engaged in the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software. The Medication Adherence segment includes the development, manufacturing and selling of consumable medication blister cards, packaging equipment, medication synchronization platform, and ancillary products and services. Its products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name MTS, Surgichem, SureMed and the Omnicell brand.

Receive News & Ratings for Allscripts Healthcare Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.